Breast cancer 'game changer' here - but only for women who can afford it - (New Zealand Herald via NewsPoints Desk)

  • While Pfizer's Ibrance was recently approved for use in New Zealand for women with advanced hormone receptor positive and HER2-negative breast cancer, it is only available for those who can afford it, New Zealand Herald reported Sunday.

  • Breast cancer charity Breast Cancer Aotearoa Coalition chairwoman Libby Burgess called the drug a "game changer," but added that "many will still miss out on this potentially life-saving medicine because it is not publicly funded."

  • "Patients are desperate to see Pharmac fund Ibrance for use in our public hospitals and we hope this will happen in the near future," she noted.

  • Sarah Fitt, Pharmac director of operations, said the agency had been "actively engaging" with Pfizer, which is the only supplier of the drug.

  • "Pharmac is looking forward to receiving a funding application, and considering Pfizer's medical evidence in depth," Fitt added.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.